On May 28, Ascentage Pharma fell 6.24% in regular trading, trading at 37.48 HKD/share, with trading volume of approximately 105 million HKD.

Within the Biotechnology sector where Ascentage Pharma belongs, the sector broadly came under selling pressure. Among individual stocks, INNOVENT BIO down 4.94%, AKESO down 4.51%, BEIGENE down 2.93%, 3SBIO down 7.34%, PEGBIO CO-B up 0.45%. The widespread decline across major biotech names suggests sector-level headwinds rather than company-specific catalysts.

On the company front, Ascentage Pharma recently announced it received approval from the Hong Kong Stock Exchange to remove the B marker from its stock code effective June 1, having met the market cap and revenue requirements under Listing Rule 8.05. The company also disclosed six clinical research abstracts accepted for presentation at the ASCO Annual Meeting taking place May 29 through June 2.

Ascentage Pharma is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. Core products include Olverembatinib and Lisaftoclax (APG-2575), targeting CML, AML, CLL, and MDS.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)